The future of sublingual immunotherapy.

F. Marcucci, M. Duse, F. Frati, C. Incorvaia, G. L. Marseglia, M. La Rosa

Research output: Contribution to journalArticle

Abstract

Sublingual immunotherapy (SLIT) is currently the most prescribed form of allergen immunotherapy in many European countries. Its use has been accepted in the international consensus publications, and recently also the scepticism of USA scientists is attenuated. Still, this treatment may be improved, and the possible developments consist of modification of the materials, use of adjuvants and use of recombinant allergens. Moreover, new applications of SLIT, such as food allergy, seem promising. Concerning materials, the future form of SLIT is likely to be represented by tablets, which were already tested for efficacy and safety with grass pollen extracts, and are likely to increase the convenience for the patient by the use of no-updosing schedule. Adjuvants fitting with the characteristics of SLIT seem to be CpG oligodeoxynucleotides (CpG), able to interact with the Toll-like receptor 9 (TLR9) whose activation induces a Th1-like pattern of cytokine release, combination of 1,25-dihydroxyvitamin D3 plus dexamethasone (VitD3-Dex), and Lactobacillus plantarum. The approach with recombinant allergens, named component-resolved diagnosis, offers the possibility to tailor immunotherapy, which was found to be effective in two randomized trials of subcutaneous SIT (16-17), while studies with SLIT are not yet available. Regarding food allergy, an important controlled study demonstrated that SLIT with hazelnut is able to increase patients tolerance over possible reactions from inadvertent assumption of the culprit food, and warrants for further trials with other foods.

Original languageEnglish
Pages (from-to)31-33
Number of pages3
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number4 Suppl
Publication statusPublished - Oct 2009

Fingerprint

Sublingual Immunotherapy
Food Hypersensitivity
Allergens
Corylus
Toll-Like Receptor 9
Immunologic Desensitization
Lactobacillus plantarum
Food
Calcitriol
Oligodeoxyribonucleotides
Pollen
Poaceae
Immunotherapy
Dexamethasone
Tablets
Publications
Appointments and Schedules
Cytokines
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Marcucci, F., Duse, M., Frati, F., Incorvaia, C., Marseglia, G. L., & La Rosa, M. (2009). The future of sublingual immunotherapy. International Journal of Immunopathology and Pharmacology, 22(4 Suppl), 31-33.

The future of sublingual immunotherapy. / Marcucci, F.; Duse, M.; Frati, F.; Incorvaia, C.; Marseglia, G. L.; La Rosa, M.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 4 Suppl, 10.2009, p. 31-33.

Research output: Contribution to journalArticle

Marcucci, F, Duse, M, Frati, F, Incorvaia, C, Marseglia, GL & La Rosa, M 2009, 'The future of sublingual immunotherapy.', International Journal of Immunopathology and Pharmacology, vol. 22, no. 4 Suppl, pp. 31-33.
Marcucci F, Duse M, Frati F, Incorvaia C, Marseglia GL, La Rosa M. The future of sublingual immunotherapy. International Journal of Immunopathology and Pharmacology. 2009 Oct;22(4 Suppl):31-33.
Marcucci, F. ; Duse, M. ; Frati, F. ; Incorvaia, C. ; Marseglia, G. L. ; La Rosa, M. / The future of sublingual immunotherapy. In: International Journal of Immunopathology and Pharmacology. 2009 ; Vol. 22, No. 4 Suppl. pp. 31-33.
@article{05b357efc7664bb591e8d948b81ece97,
title = "The future of sublingual immunotherapy.",
abstract = "Sublingual immunotherapy (SLIT) is currently the most prescribed form of allergen immunotherapy in many European countries. Its use has been accepted in the international consensus publications, and recently also the scepticism of USA scientists is attenuated. Still, this treatment may be improved, and the possible developments consist of modification of the materials, use of adjuvants and use of recombinant allergens. Moreover, new applications of SLIT, such as food allergy, seem promising. Concerning materials, the future form of SLIT is likely to be represented by tablets, which were already tested for efficacy and safety with grass pollen extracts, and are likely to increase the convenience for the patient by the use of no-updosing schedule. Adjuvants fitting with the characteristics of SLIT seem to be CpG oligodeoxynucleotides (CpG), able to interact with the Toll-like receptor 9 (TLR9) whose activation induces a Th1-like pattern of cytokine release, combination of 1,25-dihydroxyvitamin D3 plus dexamethasone (VitD3-Dex), and Lactobacillus plantarum. The approach with recombinant allergens, named component-resolved diagnosis, offers the possibility to tailor immunotherapy, which was found to be effective in two randomized trials of subcutaneous SIT (16-17), while studies with SLIT are not yet available. Regarding food allergy, an important controlled study demonstrated that SLIT with hazelnut is able to increase patients tolerance over possible reactions from inadvertent assumption of the culprit food, and warrants for further trials with other foods.",
author = "F. Marcucci and M. Duse and F. Frati and C. Incorvaia and Marseglia, {G. L.} and {La Rosa}, M.",
year = "2009",
month = "10",
language = "English",
volume = "22",
pages = "31--33",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "4 Suppl",

}

TY - JOUR

T1 - The future of sublingual immunotherapy.

AU - Marcucci, F.

AU - Duse, M.

AU - Frati, F.

AU - Incorvaia, C.

AU - Marseglia, G. L.

AU - La Rosa, M.

PY - 2009/10

Y1 - 2009/10

N2 - Sublingual immunotherapy (SLIT) is currently the most prescribed form of allergen immunotherapy in many European countries. Its use has been accepted in the international consensus publications, and recently also the scepticism of USA scientists is attenuated. Still, this treatment may be improved, and the possible developments consist of modification of the materials, use of adjuvants and use of recombinant allergens. Moreover, new applications of SLIT, such as food allergy, seem promising. Concerning materials, the future form of SLIT is likely to be represented by tablets, which were already tested for efficacy and safety with grass pollen extracts, and are likely to increase the convenience for the patient by the use of no-updosing schedule. Adjuvants fitting with the characteristics of SLIT seem to be CpG oligodeoxynucleotides (CpG), able to interact with the Toll-like receptor 9 (TLR9) whose activation induces a Th1-like pattern of cytokine release, combination of 1,25-dihydroxyvitamin D3 plus dexamethasone (VitD3-Dex), and Lactobacillus plantarum. The approach with recombinant allergens, named component-resolved diagnosis, offers the possibility to tailor immunotherapy, which was found to be effective in two randomized trials of subcutaneous SIT (16-17), while studies with SLIT are not yet available. Regarding food allergy, an important controlled study demonstrated that SLIT with hazelnut is able to increase patients tolerance over possible reactions from inadvertent assumption of the culprit food, and warrants for further trials with other foods.

AB - Sublingual immunotherapy (SLIT) is currently the most prescribed form of allergen immunotherapy in many European countries. Its use has been accepted in the international consensus publications, and recently also the scepticism of USA scientists is attenuated. Still, this treatment may be improved, and the possible developments consist of modification of the materials, use of adjuvants and use of recombinant allergens. Moreover, new applications of SLIT, such as food allergy, seem promising. Concerning materials, the future form of SLIT is likely to be represented by tablets, which were already tested for efficacy and safety with grass pollen extracts, and are likely to increase the convenience for the patient by the use of no-updosing schedule. Adjuvants fitting with the characteristics of SLIT seem to be CpG oligodeoxynucleotides (CpG), able to interact with the Toll-like receptor 9 (TLR9) whose activation induces a Th1-like pattern of cytokine release, combination of 1,25-dihydroxyvitamin D3 plus dexamethasone (VitD3-Dex), and Lactobacillus plantarum. The approach with recombinant allergens, named component-resolved diagnosis, offers the possibility to tailor immunotherapy, which was found to be effective in two randomized trials of subcutaneous SIT (16-17), while studies with SLIT are not yet available. Regarding food allergy, an important controlled study demonstrated that SLIT with hazelnut is able to increase patients tolerance over possible reactions from inadvertent assumption of the culprit food, and warrants for further trials with other foods.

UR - http://www.scopus.com/inward/record.url?scp=77649330885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649330885&partnerID=8YFLogxK

M3 - Article

C2 - 19944008

AN - SCOPUS:77649330885

VL - 22

SP - 31

EP - 33

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 4 Suppl

ER -